1123 related articles for article (PubMed ID: 26131622)
61. Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients.
Nordström AL; Farde L
J Clin Psychopharmacol; 1998 Aug; 18(4):305-10. PubMed ID: 9690696
[TBL] [Abstract][Full Text] [Related]
62. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
63. Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.
de Haan L; Lavalaye J; Linszen D; Dingemans PM; Booij J
Am J Psychiatry; 2000 Jun; 157(6):1019-20. PubMed ID: 10831489
[TBL] [Abstract][Full Text] [Related]
64. Effect of risperidone on high-affinity state of dopamine D2 receptors: a PET study with agonist ligand [11C](R)-2-CH3O-N-n-propylnorapomorphine.
Kodaka F; Ito H; Takano H; Takahashi H; Arakawa R; Miyoshi M; Okumura M; Otsuka T; Nakayama K; Halldin C; Farde L; Suhara T
Int J Neuropsychopharmacol; 2011 Feb; 14(1):83-9. PubMed ID: 20860881
[TBL] [Abstract][Full Text] [Related]
65. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
Mamo D; Kapur S; Shammi CM; Papatheodorou G; Mann S; Therrien F; Remington G
Am J Psychiatry; 2004 May; 161(5):818-25. PubMed ID: 15121646
[TBL] [Abstract][Full Text] [Related]
66. Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data.
Moriguchi S; Bies RR; Remington G; Suzuki T; Mamo DC; Watanabe K; Mimura M; Pollock BG; Uchida H
J Clin Psychopharmacol; 2013 Oct; 33(5):682-5. PubMed ID: 23899638
[TBL] [Abstract][Full Text] [Related]
67. D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia.
Uchida H; Rajji TK; Mulsant BH; Kapur S; Pollock BG; Graff-Guerrero A; Menon M; Mamo DC
J Clin Psychopharmacol; 2009 Dec; 29(6):571-5. PubMed ID: 19910723
[TBL] [Abstract][Full Text] [Related]
68. Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up.
Kimura H; Kanahara N; Sasaki T; Komatsu N; Ishige M; Muneoka K; Ino H; Yoshimura K; Yamanaka H; Suzuki T; Komatsu H; Watanabe H; Shimizu E; Iyo M
J Psychopharmacol; 2016 Aug; 30(8):795-802. PubMed ID: 27371496
[TBL] [Abstract][Full Text] [Related]
69. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.
Pilowsky LS; Busatto GF; Taylor M; Costa DC; Sharma T; Sigmundsson T; Ell PJ; Nohria V; Kerwin RW
Psychopharmacology (Berl); 1996 Mar; 124(1-2):148-53. PubMed ID: 8935810
[TBL] [Abstract][Full Text] [Related]
70. Evaluation of dopamine D
Sakayori T; Tateno A; Arakawa R; Kim WC; Okubo Y
Psychopharmacology (Berl); 2021 May; 238(5):1343-1350. PubMed ID: 33180175
[TBL] [Abstract][Full Text] [Related]
71. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine.
Kapur S; Roy P; Daskalakis J; Remington G; Zipursky R
Am J Psychiatry; 2001 Feb; 158(2):311-4. PubMed ID: 11156818
[TBL] [Abstract][Full Text] [Related]
72. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment.
Wright P; Lindborg SR; Birkett M; Meehan K; Jones B; Alaka K; Ferchland-Howe I; Pickard A; Taylor CC; Roth J; Battaglia J; Bitter I; Chouinard G; Morris PL; Breier A
Can J Psychiatry; 2003 Dec; 48(11):716-21. PubMed ID: 14733451
[TBL] [Abstract][Full Text] [Related]
73. Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.
Matsui-Sakata A; Ohtani H; Sawada Y
Drug Metab Pharmacokinet; 2005 Jun; 20(3):187-99. PubMed ID: 15988121
[TBL] [Abstract][Full Text] [Related]
74. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
Bernardo M; Parellada E; Lomeña F; Catafau AM; Font M; Gómez JC; López-Carrero C; Gutiérrez F; Pavía J; Salamero M
Psychiatry Res; 2001 Aug; 107(2):87-97. PubMed ID: 11530275
[TBL] [Abstract][Full Text] [Related]
75. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.
Kegeles LS; Slifstein M; Frankle WG; Xu X; Hackett E; Bae SA; Gonzales R; Kim JH; Alvarez B; Gil R; Laruelle M; Abi-Dargham A
Neuropsychopharmacology; 2008 Dec; 33(13):3111-25. PubMed ID: 18418366
[TBL] [Abstract][Full Text] [Related]
76. Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study.
Bressan RA; Erlandsson K; Jones HM; Mulligan RS; Ell PJ; Pilowsky LS
J Clin Psychopharmacol; 2003 Feb; 23(1):5-14. PubMed ID: 12544369
[TBL] [Abstract][Full Text] [Related]
77. Mechanism of new antipsychotic medications: occupancy is not just antagonism.
Grunder G; Carlsson A; Wong DF
Arch Gen Psychiatry; 2003 Oct; 60(10):974-7. PubMed ID: 14557141
[TBL] [Abstract][Full Text] [Related]
78. No regional difference in dopamine D2 receptor occupancy by the second-generation antipsychotic drug risperidone in humans: a positron emission tomography study.
Ito H; Arakawa R; Takahashi H; Takano H; Okumura M; Otsuka T; Ikoma Y; Shidahara M; Suhara T
Int J Neuropsychopharmacol; 2009 Jun; 12(5):667-75. PubMed ID: 18937879
[TBL] [Abstract][Full Text] [Related]
79. Long-term stability of measuring D(2) receptors in schizophrenia patients treated with antipsychotics.
Uchida H; Graff-Guerrero A; Mulsant BH; Pollock BG; Mamo DC
Schizophr Res; 2009 Apr; 109(1-3):130-3. PubMed ID: 19179049
[TBL] [Abstract][Full Text] [Related]
80. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics.
Takano A; Suhara T; Ikoma Y; Yasuno F; Maeda J; Ichimiya T; Sudo Y; Inoue M; Okubo Y
Int J Neuropsychopharmacol; 2004 Mar; 7(1):19-26. PubMed ID: 14764214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
